DNLI Q3 2023 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-64.4% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$114M-8981.5% margin

Net Income

-$99M-7841.6% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

-99.6%

Cash Flow

Operating Cash Flow

-$87M

Free Cash Flow

-$89M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$118M

Stockholders' Equity

$1.1B

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$4M	-64.4%
Gross Profit	$1M	$4M	-64.4%
Operating Income	-$114M	-$107M	-5.9%
Net Income	-$99M	-$103M	+3.8%